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Creating a United Front: Harmonizing the
United States Regulatory Policies Surrounding
Human Embryonic Stem Cell Research
Sydney Kossow*
ABSTRACT
Stem cell therapy is an imperative development in science and medicine
that is heavily regulated worldwide. With the potential to cure illnesses, help
understand disease development, and advance regenerative medicine, a harmonized regulatory policy is crucial to capitalize on the benefits of stem
cells. This article examines an important topic of discussion surrounding
stem cell therapy and research: the political debate on how and when embryonic stem cells can be used. In addition to examining ethical challenges, this
article discusses the legal challenges surrounding using embryonic stem cells
to inform regenerative therapies. Specifically, this article will examine the
National Institute of Health’s Guidelines for Human Stem Cell Research and
the historic avenues of federal and state legislation to regulate the use of
these cells in research. This article discusses the internal and external inconsistencies of the United States’ current regulation of embryonic stem cells
and how the divide between states is problematic for the United States’ completive stance in developmental science and medicine. Finally, this article
contemplates a cohesive regulatory system influenced by individual states
and other countries that currently lead the medical field, to form a united
front in approaching the use of stem cells.
I.

INTRODUCTION

In December 2012, Kyle and Carla Poppleton were expecting their first
child.1 The couple, who lived in Botswana, decided to collect their new
baby’s cord blood and tissue cells to take advantage of the new advanced
form of medicine, stem cell therapy, and safeguard their new child’s health.2
In March 2013, the Poppletons welcomed their daughter Paige into the
world.3 Within just a year Paige was diagnosed with cerebral palsy, and by
the next six months she could not sit up and kept her right hand in a fist
shape most of the time.4 In April 2014, Paige’s umbilical cord blood stem
cells were transferred to Duke University in North Carolina, where the cells
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Shamshad Ahmed, How Stem Cell Therapy Changed Our Lives, SMART CELLS
(Dec. 19, 2017), https://www.smartcells.com/how-stem-cell-therapy-changedour-lives-three-real-life-stories/ [https://perma.cc/8WY7-F6Z4].
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were transplanted and reinfused into Paige’s body.5 Two months after the
infusion Paige began crawling, pulling herself to stand up, and holding her
parents hands once again.6 This story, and thousands of others like it, is an
encouraging endorsement of stem cell research and the life-changing healing
powers it has and can continue to provide in the medical space.7
Stem cell therapy is a groundbreaking part of science and medicine taking over the globe.8 Stem cells show great promise in aiding to find cures for
illnesses, understand the development of diseases, and advance regenerative
treatment in ways that no other scientific research has been able to do.9 While
certain aspects of stem cell therapy and research are legal in the U.S., the use
of stem cells, and more specifically the use of embryonic stem cells, has been
heavily restricted through legislation and regulation.10 Although there is a
bright future for human embryonic stem cell research, its development is
halted by many legal and ethical challenges.11 This article will first look at
the history of stem cell research and its growing potential in the medical
science realm. Next, this article will unpack legal issues surrounding the use
of stem cells in regenerative research and therapy and introduce policy arguments for and against the legality of embryonic stem cell research. This article will also touch on how the internal and external inconsistencies of U.S.
regulation surrounding stem cell research impede biotechnology advances.12
Lastly, this article will focus on stem cell regulations across the globe and
explore what a new regulation system in the U.S. might look like with the
influence of other countries and individual states that are currently leading
the medical field.

5.

Id.

6.

Id.

7.

See Ahmed, supra note 1.

8.

See Piotr Rewerski, The Need for a New U.S. Stem Cell Research Policy: A
Comparative Look at International Stem Cell Research Laws, 2007 U. ILL. J.L.
TECH. & POL’Y 415, 417–18 (2007).

9.

See id.

10.

See id. at 418.

11. Li Jiang, Will Diversity Regulations Disadvantage Human Embryonic Stem
Cell Research: A Comparison Between the European Union and the United
States, 25 DEPAUL J. ART, TECH. & INTELL. PROP. L. 53, 55 (2014).
12.

Id.
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WHAT IS STEM CELL THERAPY?

What Are Stem Cells?

A stem cell is a single cell from the human body with the capacity to
replicate itself (self-renew) and differentiate itself into various cell types.13
The characteristic of differentiating itself is also known as “specializing.”14
Stem cells are considered unspecialized, meaning they can transform into
specialized types of cells like bone or muscle cells.15
There are two main types of stem cells: embryonic and adult.16 Embryonic stem cells are derived from embryos and have virtually unlimited potential to replicate into every kind of cell in the body, a characteristic known as
“pluripotent.”17 Deriving embryonic stem cells requires the embryo to be destroyed, which has sparked many of the legal and ethical arguments discussed later in this article.18 Three types of embryos are currently being
pursued when it comes to stem cell research: (1) embryos intended to create a
child, (2) embryos created in the process of in vitro fertilization (IVF) but not
implanted, and (3) embryos created specifically for research purposes.19 The
use of embryonic stem cells is legal in some states; however, it is heavily
restricted, and this article will discuss this further in the following sections.20
On the other hand, adult stem cells can be extracted from certain types
of tissue with minimal bodily intrusion.21 The extraction of adult stem cells is
thus less controversial because it does not require destroying any organism.22
The drawback to adult stem cells is that they are “multipotent,” meaning they
can only replicate a limited number of other types of cells in comparison to
13. Sylvia E. Simson, Breaking Barriers, Pushing Promise: America’s Need for an
Embryonic Stem Cell Regulatory Scheme, 34 BROOK. J. INT’L L. 531, 537
(2009).
14.

Id.

15. Allison B. Newhart, The Intersection of Law and Medicine: The Case for Providing Federal Funding for Embryonic Stem Cell Research, 49 VILL. L. REV.
329, 330 (2004).
16.

Id.

17. Amy Miller, The Effect of Federal Funding Restrictions for Embryonic Stem
Cell Research on Colleges and Universities: The Need for Caution When Ethical Objections to Research Are Raised, 41 J.C. & U.L. 147, 154–55 (2015).
18.

Id. at 153.

19. Christopher Ogolla, Reversing the United States Policy on Human Embryonic
Stem Cell Research: A Case of Science, Law and Policy, or Just Plain Politics,
35 T. MARSHALL L. REV. 91, 94 (2009).
20.

See generally Rewerski, supra note 8.

21. Miller, supra note 17, at 154.
22.

Id.
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embryonic cells.23 Scientists have recently succeeded in transforming adult
cells into stem cells that act similarly to embryonic cells using genetic
reprogramming.24 While this provides exciting hope for the future of stem
cell therapy, scientists have yet to ensure the safety of this process and cannot definitively say whether using reprogrammed adult cells will cause adverse effects on the human body.25
Without the reassurance that reprogrammed adult cells are safe to use in
the human body, many researchers advocate for the use of embryonic stem
cells.26 Researchers tend to prefer the use of embryonic stem cells over adult
stem cells for a few other main reasons: (1) embryonic stem cells are pluripotent and have the potential to differentiate into any specialized human cell
type; (2) embryonic stem cells have the ability to grow into large numbers of
specialized cells through a controlled laboratory setting; and (3) embryonic
stem cells are abundant in comparison to adult cells.27 While researchers
have been surprised at the adaptability and promise of working with adult
stem cells, adult stem cells are more likely to contain abnormalities and often
carry a risk to humans due to the environmental hazards of cell replication.28
These reasons weigh in favor of using embryonic stem cells over adult cells
for the time being when it comes to regenerative medicine.29
B.

How Do Stem Cells Work?

Stem “cell therapy focuses on aiding the regeneration process of the
muscle cells” in the body.30 Researchers can grow stem cells in a lab,
manipulating them into specific types of cells to be used to repair the response system of diseased, dysfunctional, or injured tissue.31 Most stem cells
have the ability to transform by separating without limit, dividing, and transforming into a new kind of cell.32
23. Edward A. Fallone, Funding Stem Cell Research: The Convergence of Science,
Religion & Politics in the Formation of Public Health Policy, 12 MARQ.
ELDER’S ADVISOR 247, 253–54 (2011).
24.

Stem Cells: What They Are and What They Do, MAYO CLINIC, (Mar. 19, 2022),
https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/
stem-cells/art-20048117 [https://perma.cc/7FLS-AWKP].

25.

Id.

26.

See id.

27. Newhart, supra note 15, at 331.
28.

MAYO CLINIC, supra note 24.

29.

See id.

30. NEIL H. RIORDAN, STEM CELL THERAPY A RISING TIDE: HOW STEM CELLS
ARE DISRUPTING MEDICINE AND TRANSFORMING LIVES 9 (2017).
31.

MAYO CLINIC, supra note 24.

32. Samuel D. Hodge, Jr., A Medical/Legal Perspective on Stem Cell Therapy: A
Scientific Breakthrough or Snake Oil, 83 ALB. L. REV. 89, 90 (2019–2020).
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There are four outcomes that can happen with the life of a stem cell.33
The first fate is a common one, being that the stem cell remains inactive, thus
not dividing or differentiating into any other kind of cell.34 The second fate of
a stem cell is called symmetric self-renewal; in this situation the parent cell
divides into two daughter cells that are exactly the same as the parent cell.35
While this fate is not considered differentiation, it does increase the pool of
specialized stem cells that can then be used for differentiation in the future.36
Thirdly, a stem cell can participate in what is called asymmetric self-renewal.37 Similar to symmetric self-renewal, asymmetric self-renewal results
in a parent stem cell dividing into two daughter cells; however, in this instance, one daughter cell is a copy of the parent and the other is a more
specialized cell named a progenitor cell.38 This progenitor cell can then be
used for natural tissue development or regeneration and also provides the
benefit of maintaining the stem cell pool for the future.39 The fourth fate of a
stem cell is when a stem cell divides into two daughter cells, but both daughter cells are differentiated from the parent cell.40 While this process does not
maintain the stem cell pool it does result in a greater proliferation of differentiated cells for tissue development or regeneration.41
After a stem cell has been transformed into a specialized cell, through
one of the processes described above, it can then be implanted into a person
to start the regeneration process.42
C.

Why Are Stem Cells Becoming Popular, And Why Does Anyone
Care?

This form of medicine is making headlines because there are endless
amounts of benefits derived from using stem cell therapy in the medicinal
sphere.43 These benefits include an increase in the understanding of how diseases occur, development and testing of new drugs, tissue regeneration, and
33. Jesse K. Biehl & Brenda Russell, Introduction to Stem Cell Therapy, NATIONAL INSTITUTES OF HEALTH PUBLIC ACCESS (July 21, 2014), https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC4104807/ [https://perma.cc/EW8UZLFR].
34.

Id.

35.

Id.

36.

Id.

37.

Id.

38.

Id.

39. Biehl & Russell, supra note 33.
40.

Id.

41.

Id.

42.

See generally MAYO CLINIC, supra note 24.

43.

Id.
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cures for diseases that are a significant area of focus for the medical community around the world.44
Researchers and doctors hope to better understand the processes in
which diseases and conditions develop in the human body by watching stem
cells mature into differentiated cells such as heart muscles, nerves, and other
tissues or organs.45 Additionally, by testing new drugs on stem cells, scientists and researchers can determine whether a new drug is safe for humans,
which could potentially provide some solutions to ethical issues that surround drug and treatment testing on animals and humans.46
A wide range of people might benefit from stem cell therapies, including but not limited to people with spinal cord injuries, diabetes, Parkinson’s
disease, Alzheimer’s disease, heart disease, cancer, strokes, and many
more.47 But stem cells do not only concern patients.48 Stem cell research has
become a popular and controversial topic because it “necessitates decisions
from the political, legal, ethical, and religious realms,” making it an important issue for many different groups of people outside of the medical field.49
III.

LEGALITY AND REGULATORY CONCERNS REGARDING
EMBRYONIC STEM CELLS

Most of the political and legislative debate surrounding stem cell research focuses on embryonic stem cells rather than adult stem cells.50 This
has allowed adult stem cells to be used in various clinical trials without much
pushback.51 While there is controversy in the scientific world regarding the
capabilities of embryonic in comparison to adult stem cells, some scientists
believe that adult stem cells have the power to do anything that can be accomplished with embryonic stem cells.52 However, until scientists find a way
to use adult stem cells in the same way that they could use embryonic stem
cells, by transforming them into any type of cell, the superior therapeutic
power of embryonic stem cells, and the debate regarding their legality, will
continue in full force.53
44.

Id.

45.

Id.

46.

See id.

47.

Id.

48.

See Chelsea L. Gulinson, Embryonic Stem Cell Tourism, 58 JURIMETRICS J. 17,
41 (2017).

49.

Id.

50. Hodge, supra note 32, at 93.
51.

Id. at 94.

52. Simson, supra note 13, at 539.
53.

See id.
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Due to the fact that there are extremely polarized beliefs regarding stem
cell research, “political branches have been locked in a stalemate” for the
past thirty years when it comes to administrative policy.54 Furthermore, successive U.S. presidents have fallen on both sides of the polarized debate,
leading to inconsistent administrative policies.55
The regulation of stem cell research and therapies in the U.S. thus operates at both the federal and state levels.56 Because the U.S. has no uniform
regulation at the federal level, state legislators took matters into their own
hands by developing differentiated state regulations.57 These varying policies
create an incohesive system, hindering the ability of the U.S. to capitalize on
this field of science and medicine.58 Additionally the varying policies
threaten cooperative attempts between the states to progress together in scientific studies of stem cells.59
A.

National Institutes of Health Guidelines for Human Stem Cell
Research

In 1985, Congress enacted a ban on most fetal research thereby banning
research on embryonic stem cells.60 Following the 1985 ban, Congress
amended the National Institute of Health’s (NIH) appropriations bill, which
is the primary source of federal funding for medical and life science research
projects throughout the U.S.61 In 1995, the Dickey-Wicker Amendment was
added to the NIH appropriations bill, which prohibited the use of any federal
funds for any research that destroys or endangers human embryos.62 To harvest new stem cells the embryo must be destroyed.63 Therefore, the DickeyWicker Amendment meant that federal funding would be permitted only in
cases where embryonic stem cells had already been extracted BEFORE the
project’s funding began.64
President Bush announced an executive order in 2001, easing the
Dickey-Wicker strain on stem cell research and allowing federal funds to be
54. Gulinson, supra note 48, at 33.
55.

Id.

56. Jiang, supra note 11, at 78.
57.

Id. at 79.

58.

Id.

59.

Id. at 88.

60. Thomas W. Mayo, Embryonic and Fetal-Cell Research, 1 HEALTH L. PRAC.
GUIDE § 15:20 (2022).
61. Miller, supra note 17, at 148–49.
62.

Id.

63.

See id. at 149.

64.

Id.
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awarded for research that used human embryonic stem cell lines.65 However,
to be awarded the federal funds, the embryonic stem cell lines had to meet
certain criteria, for example, “when the life and death decision has already
been made.”66 This expanded the ability of research to be done on some
embryonic stem cells, yet only sixty cell lines met the specifications for this
executive order.67 Bush’s policy did not affect private or state-funded research, nor did it affect adult stem cell research.68
A few years later, President Bush vetoed the Stem Cell Research Enhancement Act of 2007 (2007 Act), which was aimed at amending the Public
Health Service Act to provide for human embryonic stem cell research.69 The
2007 Act explicitly endorsed human embryonic stem cell research, stating
that such research would be federally funded and the Secretary would conduct the research.70 Had President Bush not vetoed the 2007 Act, federal
funding for stem cell research would have expanded to include stem cells
created for, but not used in, the in vitro fertilization (IVF) process.71
After Bush left office in 2009, President Obama issued an executive
order which removed barriers created by President Bush’s previous executive
order.72 Obama’s executive order made room for federal funding from the
NIH, but it did not come without limits.73 President Obama placed three general restrictions on the use of embryos for stem cell research, including that
research had to be (1) done responsibly, (2) scientifically worthy, and (3)
permitted by law.74
In response to President Obama’s executive order, the NIH published
draft guidelines for federal funding using human embryonic stem cells in
order to impose restrictions on research.75 These restrictions stated that, in
accordance with Dickey-Wicker, no NIH funding would be given to support
the derivation of stem cells from human embryos, but funding would be
granted for research done on embryonic stem cells that had already been
65. Ogolla, supra note 19, at 99.
66. Mayo, supra note 60.
67.

Id.

68.

A Brief History of U.S. Stem Cell Policy, RESEARCH AMERICA, https://
www.researchamerica.org/advocacy-action/issues-researchamerica-advocates/
stem-cell-research/brief-history-us-stem-cell (last visited September 7, 2022)
[https://perma.cc/2TTQ-W7BQ].

69. Simson, supra note 13, at 551-52.
70.

Id. at 551.

71.

RESEARCH AMERICA, supra note 68.

72.

Id.

73.

See Miller, supra note 17, at 173.

74.

Id.

75.

Id. at 174.
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derived.76 Therefore, even after lifting the restrictions placed during Bush’s
presidency, President Obama’s executive order was still being limited by the
Dickey-Wicker Amendment.77 The Dickey-Wicker Amendment remains the
primary regulatory construct under which the federal government restricts
funding regarding embryonic research today.78
The D.C. Circuit upheld the NIH’s guidelines regarding embryonic stem
cells in Sherley v. Sebelius.79 In Sebelius, researchers brought a claim arguing
the NIH guidelines violated the Dickey-Wicker Amendment because previous decisions by the NIH to fund embryonic stem cell research should be
considered null and void.80 The district court concluded that stem cell research did not violate the Dickey-Wicker Amendment.81 The court reasoned
that the Dickey-Wicker Amendment bars funding for the destruction of an
embryo in the act of deriving an embryonic stem cell; however, it does not
explicitly prohibit the funding of research in which an embryonic stem cell
will be used.82 In holding this, the D.C. Circuit stated that an embryonic stem
cell that was previously derived from an embryo is not an “embryo” for the
purposes of the Dickey-Wicker Amendment.83
Since President Obama’s executive order in 2009, a few other noteworthy issues have been regulated.84 In 2016, President Obama signed the 21st
Century Cures Act into law, which in part provided to assure the timely review of regenerative therapies, including research done through stem cells.85
Then in 2019, the Department of Health and Human Services (HHS) issued a
new policy that ended the allowance under NIH for intermural fetal tissue
research.86 Additionally, the policy enacted by HHS established an Ethics
Advisory Board that evaluates all future extramural fetal tissue research
projects, including those involving stem cells, and determines whether the
projects should receive federal funding.87 In 2020, the Ethics Advisory Board
evaluated fourteen “extramural research proposals involving fetal tissue,”
76.

Id.

77.

Id.

78.

See id. at 149.

79. Miller, supra note 17, at 175.
80. E. Johnathan Mader, The Wholesale Human: The Ineffectuality of Responsive
Regulation to Advancements in Reproductive Biotechnology Post Roe v. Wade,
42 U. ARK. LITTLE ROCK. L. REV. 203, 215 (2019).
81.

Id.; Miller, supra note 17, at 175.

82. Sherley v. Sebelius, 644 F.3d 388, 390 (2011).
83.

Id. at 395.

84.

See RESEARCH AMERICA, supra note 68.

85.

Id.

86.

Id.

87.

Id.
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and only one of the fourteen proposals was recommended to receive federal
funding.88 Finally, and arguably most important, in 2021, HHS amended its
2019 policy to no longer require an Ethics Advisory Board review for fetal
tissue research and also allowed intramural research involving fetal tissue to
resume.89
B.

Federal Legislation
1.

The FDA’s Control over Stem Cells

Today, the U.S. Food and Drug Administration (FDA) regulates the progress of stem cell research and therapy.90 Scientists would argue that stem
cell research should be governed as a practice of medicine rather than as a
drug, but a U.S. Court of Appeals holds otherwise.91 In 2014, the case of
United States v. Regenerative Sciences LLC et al. was decided by a threejudge panel from the D.C. Court of Appeals.92 The court held that a treatment
made from a patient’s own processed stem cells constitutes a drug and is
subject to regulation by the FDA.93
In addition to the case noted above, three statutes give the FDA regulatory authority over stem cell treatments.94 These three statutes are the Federal
Food, Drug, and Cosmetic Act (FD&C Act), the Public Health Services Act
(PHSA), and the 21st Century Cures Act.95 The FD&C Act allows the FDA
to regulate any drugs or devices intended for use regarding diagnosis, cure,
treatment, or prevention of disease, along with any effect to the structure or
function of the body.96 For a new drug to be approved under the FD&C Act,
the drug or device must prove safe and effective through clinical trials.97
Section 351 of the PHSA gives the FDA the authority to regulate interstate commerce that involves biological products, including any product used
to prevent, treat, or cure a disease or condition of a human.98 Section 361 of
88.

Id.

89.

Id.

90.

See Appeals Court Affirms That Stem-Cell Therapy is a Drug: United States v.
Regenerative Sciences, 30 No. 1 WESTLAW J. PHARM. 5, Feb. 21, 2014, at 1.

91.

See id.

92.

Id.

93.

See id.

94. Sydney Hope, Comment, When Miracle Cures Go Bad: Regulators’ Responses
to Unproven Direct-to-Consumer Stem Cell Therapies, 23 SMU SCI. & TECH.
L. REV. 257, 263 (2020).
95.

Id.

96.

Id.

97.

Id.

98.

Id. at 264.
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PHSA allows the FDA to regulate in a manner necessary to prevent the introduction, transmission, or spread of diseases.99
Lastly, the 21st Century Cures Act creates a fast track review of definitive medicine if such a drug meets three criteria: (1) it is a regenerative therapy as defined by the Act, (2) it is “intended to treat, modify, reverse, or cure
a serious life-threatening disease or condition,” and (3) preliminary evidence,
done through clinical trials, shows that the drug has potential to address unmet medical needs regarding said disease or condition.100
2.

Stem-Cell Treatment Approval

By 2017, the only clinical pathway in the U.S. able to permit the use of
stem cell research was the costly $1.2 billion route that allows for a new drug
to be approved.101 The big issue with this route is that since stem cells are not
patentable, because they come from the human body, pharmaceutical companies are not interested in investing in the research.102 If a pharmaceutical
company were to bring a product to market, they essentially would not be
able to exclusively own the product since no patent would be granted, therefore, getting funding is intrinsically difficult when it comes to bringing a new
stem cell product to market.103
A regulatory path outside of clinical trials is as an investigational new
drug (IND), which costs $700,000 for the application process alone.104 By
reason of these limited pathways, some scientists believe that the FDA’s
overreach into the regenerative medicine research area is stunting potential
growth in an important frontier of science and medicine.105
“Thousands of stem cell trials have been completed or are ongoing,”
investigating “new combinations of stem cell products” for a range of diseases and conditions, which promises great progress to the world of regenerative medicine.106 However, despite this progress, the FDA has only
approved one stem cell product, hematopoietic.107 Hematopoietic stem cells
are blood-forming stem cells taken from cord blood and used to reconstitute
a patient’s blood and immune system after harsh treatments, such as radiation

99.

Id.

100. Hope, supra note 94, at 264.
101. RIORDAN, supra note 30, at 231.
102. Id. at 232.
103. See id.
104. Id.
105. See id. at 233.
106. Sarah Duranske, Reforming Regenerative Medicine Regulation, 34 GA. ST. U.
L. REV. 631, 636 (2018).
107. Id.
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or chemotherapy.108 Even though the only FDA-approved stem cell therapy is
for diseases of the hematopoietic system, other stem cell therapies are being
marketed through direct-to-consumer advertising.109 For example, in 2021,
295 stem cell clinics located in the U.S. provided therapies without adequately disclosing the risk, efficacy, or regulatory approval status.110 It follows that the FDA’s attention to safety and efficiency during the drug
application process is effectively slowing down the process of getting safe
therapies to consumers, which allows clinical studies that have not proven
their safety to monopolize the field.111
3.

The International Society for Stem Cell Research

While not federal legislation, the International Society for Stem Cell
Research (ISSCR) is considered the voice of the stem cell research community internationally and provides ethical and medical standards for researchers to follow when working with embryonic stem cells.112 The ISSCR
guidelines from 2016 prohibited research from being conducted on embryos
fourteen days post-cultivation.113 Most countries also follow some range of a
fourteen day limit for using an embryo.114 In May 2021, however, the ISSCR
announced that it no longer endorses the international standard limiting embryonic research to fourteen days after fertilization.115 Now the ISSCR leaves
it up to the public, including national academies of science, academic societies, funders, and regulators to engage in scientific, societal, and ethical conversations to decide whether the fourteen day limit should be extended to
projects depending on research objectives.116

108. Id.
109. Leah Nadel, Comment, The Future of Stem Cell Therapy Regulation Under the
FDA’s Comprehensive Regenerative Medicine Policy Framework Through a
Public Health Lens, 21 HOUS. J. HEALTH L. & POL’Y 223, 233 (2021).
110. Id.
111. See id.
112. See Françoise Baylis, Stem Cell Research Community Drops 14-Day Limitation
on Human Embryo Research, DALHOUSIE UNIVERSITY NEWS (June 1, 2021)
https://www.dal.ca/news/2021/06/01/stem-cell-research-community-drops-14day-limit-on-human-embryo-.html#:~:text=stem%20cell%20research%20com
munity%20drops%2014%E2%80%91day%20limit%20on%20human%20em
bryo%20research,-Fran%C3%A7oise%20Baylis%20%2D%20June&text=appli
cations%20of%20this%20research%20include,of%20embryos%20beyond%20
14%20days [https://perma.cc/657K-JKR9].
113. Id.
114. Id.
115. Id.
116. Id.
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State Legislation

Without a coordinated effort regarding stem cell research regulation
from the U.S. Federal Government, the states are left to regulate independently.117 Each state must answer the principal question of whether to permit
or prohibit embryonic stem cell research.118
As of 2015, twenty-five states had enacted some type of regulation that
banned the sale or research of embryos, fetuses, or both.119 The states who
have developed highly restrictive policies surrounding stem cell research
have statutes falling into two general categories: (1) laws aimed to discourage research involving abortions, and (2) laws aimed to preclude research
surrounding pre-implantation embryos.120 Even when some of the anti-abortion states are otherwise supportive of research, their laws could impede the
studies of embryonic stem cells that do not necessarily deal directly with
abortions.121
Some states have chosen to widely permit research, even permitting reproductive cloning, whereas others permit stem cell research more narrowly.122 Still, a handful of states have heavily restricted policies surrounding
the research.123 The wide range of policies creates an unharmonized front to
the scientific and medical world.124
1.

Differing State Approaches

Not all states have legislated on the issue of embryonic stem cell research but those that have legislated provide a guideline to understand the
polarized stances in the U.S. surrounding stem cells.125 On the one hand,
states including Arkansas, Louisiana, North Dakota, and South Dakota specifically prohibit most or all forms of embryonic stem cell research.126 On the
other hand, Iowa permits embryonic stem cell research but does not fund
it.127 California provides both a right to conduct embryonic stem cell research
117. Jiang, supra note 11, at 79.
118. Id.
119. Nefi D. Acosta & Sidney H. Golub, The New Federalism: State Policies Regarding Embryonic Stem Cell Research, 44 J.L. MED. & ETHICS 419, 430
(2016).
120. Id.
121. Id.
122. See id. at 430–31.
123. Id. at 430.
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125. See Acosta & Golub, supra note 119, at 430–31.
126. Simson, supra note 13, at 534.
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and funding.128 Then there are states in the middle, like North Carolina and
West Virginia, that have no law on the subject, and states, like Florida that
are deadlocked on the issue.129
Louisiana has the most restrictive research guidelines out of all states,
and defines an embryo not even implanted in a woman’s uterus as a “juridical person.”130 In short, Louisiana prohibits the use or destruction of embryos
for research purposes under any circumstances.131 Like Louisiana, states including South Dakota and Minnesota have statutes with similar prohibitions
if the use of the embryo subjects the embryo to a substantial risk of injury
and or death.132
Conversely, states like New Hampshire and Pennsylvania have enacted
statutes that find research and experimentation on embryonic stem cells legal.133 The Pennsylvania General Assembly proposed two bills in 2003, the
Stem Cell Research Act and the Stem Cell Research Authorization Act.134
Both of these bills allow for the research of embryos that have been donated
from those who have leftover embryos prior to in vitro fertilization procedures, so long as they have agreed to donate such embryos specifically for
obtaining stem cells for research.135
In 2004, the governor of New Jersey included a $6.5 million grant to
build a research institute dedicated to stem cell research in the state budget
allocation plan.136 This marked the first state in the U.S. to provide funding
for stem cell research.137 California is another state providing state funding
for stem cell research and proposed a ballot initiative in 2004 to raise $3
billion over the span of ten years to fund stem cell research in the state.138
With its ballot initiative (Prop 71) in 2004, California became the largest and
most influential state venturing into the realm of stem cell research, and can
be used as an example for other states and the U.S. federal legislation.139

128. Id. at 548.
129. Id. at 535.
130. Newhart, supra note 15, at 340.
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132. Id. at 340-41.
133. Id. at 341–42.
134. Id. at 342.
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136. Newhart, supra note 15, at 361.
137. Id.
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139. Acosta & Golub, supra note 119, at 418.
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California Prop 71

Prop 71 was originated by a group of wealthy and political Californians
who were raising
children with type 1 diabetes.140 Stem cells hold great promise for diabetes research and treatment, which provided a strong incentive for these
Californians to create this ballot initiative.141 Prop 71 was not only a bond
proposal it also notably amended the California Constitution to “establish a
right to conduct stem cell research which includes research involving adult
stem cells, core blood stem cells, pluripotent stem cells, and/or progenitor
cells.”142 In addition to the descriptive amendment, Prop 71 also amended the
California Constitution to create a new state agency, known as the California
Institute for Regenerative Medicine (CIRM), which controls the allocation of
grants and loans for stem cell research.143 The CIRM is also authorized to
establish regulatory standards and create oversight bodies related to stem cell
research.144
One aspect of Prop 71 that stands out from all other regulations of stem
cell research is its governance, which is overseen by an Independent Citizens
Oversight Committee (ICOC).145 While political bodies hold the oversight
powers in many other regulatory systems, oversight of CIRM is “firmly in
the hands of scientists and patients.”146 Reflecting a deep distrust of political
and governmental influence Prop 71 attempts to combat political pressures
by leaving oversight up to those directly in the line of stem cell research.147
In applying for funding and allowance to research on a line of cells,
states generally take one of two approaches.148 One is the peer review process
undertaken by states including California, Connecticut, Maryland, New
York, and Illinois.149 The other is allocations made directly to state institutions, which is the approach taken by New Jersey and Massachusetts.150
Other than coastal geography, there are several similar characteristics of
these permissive states—each houses large research universities and active
biotechnology industries, which means that these states have the resources
140. Id. at 421.
141. See id.
142. Id. at 423.
143. Id. at 424.
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for research, and can expect economic benefits from successful research and
treatment.151
3.

Why a Lack of Uniformity Among the States Matters

While states have the ability to create their own laws on stem cell research, this ability presents a downfall to the U.S. when it creates such a wide
range of policies throughout the country.152 This lack of uniformity will put
some states higher on the totem pole, both medically and economically,
while others lag behind.153 For the country as a whole, having this large of a
range of policies across the map could make the U.S. appear polarized and in
disarray, thus creating a disadvantage for being competitive in the medical
field.154
IV.
A.

ARGUMENTS FOR AND AGAINST PERMISSIVE STEM
CELL REGULATION

Opponents

Those who oppose the legality of embryonic stem cell research and therapy stand firmly on the argument that research involving embryonic stem
cells violates current law and policy because it goes against the duty to protect potential life.155 In other words, using embryos to harvest stem cells for
research purposes is immoral.156 The stem cell debates largely center around
the ethical issues of collecting and using stem cells, but this debate did not
begin solely with embryonic cells.157 The catalyst case for this debate regarding life-sustaining cells started with the U.S. Supreme Court case, Roe v.
Wade.158 In Roe, the U.S. Supreme Court held that the Constitution did not
support the view that life begins at conception.159 Under Roe, the unborn
were not considered persons, and had no constitutional right to life.160

151. Acosta & Golub, supra note 119, at 427.
152. See Simson, supra note 13, at 535.
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160. Id.; contra Dobbs v. Jackson Women’s Health Org., 142 S.Ct. 2228, 2261
(2022) (“Our [majority] opinion is not based on any view about if and when
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Public opinion and policy still seem to conflict with the Court’s holdings in Roe.161 Generally, there are at least three distinct perspectives regarding the definition of life.162 The first perspective is proudly held by the
Roman Catholic Church, which has a “long-standing belief that life starts the
second the sperm meets and combines with an egg.”163 The second is held by
scientists whose view is that life begins on a wider spectrum, ranging from
conception to birth, depending on interpretation and background.164 The third
is expressed by the Supreme Court, that a “person” does not exist at an embryonic stage.165 While each perspective has its own merit, the law provides
the ledge upon which embryonic stem cell research will be regulated.166
The Framers of the U.S. Constitution placed safeguards around scientific advancements because they understood how essential these advancements are to society.167 Due to this understanding, the Framers added Article
1, Section 8, Clause 8 to the United States Constitution, which grants Congress the power to “promote the Progress of Science and useful Arts, by
securing for limited Times to Authors and Inventors the exclusive Right to
their respective Writings and Discoveries.”168 The goal of this clause was to
promote the progress of science and to recognize the rights of authors and
inventors for limited times regarding such progress.169 While freedom of religion is also written into the Constitution, the Constitution does not permit
religion to infiltrate into the science realm.170 Furthermore, it is the states’ job
to enact specific laws for regulating and promoting science, not religious
establishments.171
B.

Proponents

Proponents of stem cell therapy argue that, from a legal perspective,
embryos are not

161. See generally Hieu The Le & Joan Catherine Bohl, The Intersection of Stem
Cell Research, the Roman Catholic Church, United States Constitutional Law,
and Public Policy, 23:1 QUINNIPIAC HEALTH L.J. 31, 33 (2020).
162. Id. at 44.
163. Id.
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166. Id. at 40.
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171. Id. at 40–41.
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legal persons and are not entitled to protections afforded to persons.172
Accordingly, proponents push that embryos should be considered property
and treated as such under the law.173 Proponents of stem cell research also
push that by funding stem cell research in the U.S., the U.S. will remain
competitive in the medical field and not fall behind other countries that are
advancing through stem cell research.174
Supporters of embryonic stem cell research argue that the benefits and
advances of stem cell research greatly outweigh the damages done by destroying embryos.175 Specifically, stem cells could be used in testing
pharmaceuticals and experimental treatments, ultimately providing safer alternatives to trials that normally would involve human subjects.176 In addition, there are hundreds of thousands of embryos being preserved in fertility
clinics that are never going to be transferred into a woman’s uterus, meaning
eventually they will be discarded.177 The argument that follows is, why not
allow for a more productive use of these discarded cells, such as stem cell
research?178
Proponents recognize that the public perception of stem cells is that they
all come from the unborn but that such perception is not necessarily true.179
There are arguably morally acceptable forms of embryonic stem cell research
outside of the misleading perception that the only way to harvest embryonic
stem cells is morally indecent.180 Embryonic stem cells can be obtained from
embryonic germ cells, which are cells from miscarriages or spontaneous
abortions (not elective abortions), umbilical cord stem cells, and placentaderived stem cells.181 When it comes to in vitro, most of the frozen embryos
have no chance of even being born.182 It could be said that using those frozen
embryos for research, which has potential for good, is a much better fate for
them than simply staying frozen until they are no longer viable.183 The immorality argument regarding embryonic stem cells carries little weight when

172. Newhart, supra note 15, at 350.
173. Id. at 350–51.
174. Id. at 348–49.
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they are harvested from cells that are no longer being used for sustaining
life.184
C.

Case Law Regarding the Legal Status of an Embryo

Case law surrounding the legality of stem cell research using embryos is
limited, however, there are a few cases that have addressed the issue.185
Courts in the U.S. generally follow either a majority or minority view.186 The
majority view is that frozen embryos are the property of the progenitors,
while the minority view holds that embryos are potential lives and thus the
law should afford them special protection as it has with other forms of human
life.187
A Tennessee case, Davis v. Davis, illustrates the minority view on embryos; the court held that embryos should be afforded special protection
under the law.188 In Davis, the court held the embryos were not considered
“persons” or “property” but declared that embryos occupy an interim category that entitles them to special respect because they hold power to potentially form into human life.189
The majority view regarding embryos is illustrated by the New York
Court of Appeals case Kass v. Kass, which held that embryos are more like
property than persons, and are the property of the progenitors.190 Other cases
such as Cahill v. Cahill have extended the holding from Kass by treating
frozen embryos as property.191 In addition to state cases, federal cases such as
York v. Jones have also held that embryos are to be treated as property in
support of the majority view.192
Federal cases have also explored whether embryos have any legal rights,
such as redress for injuries.193 In Doe v. Irvine Scientific Sales Co., the U.S.
District Court for the Eastern District of Virginia held that since embryos are
not entitled to the protections which are granted to persons, embryos are not
entitled to bring claims for injury in tort.194 Further, in Satana v. Zilog, the
U.S. Court of Appeals for the Ninth Circuit held that a nonviable fetus did
184. See id.
185. Newhart, supra note 15, at 332.
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not have the right to bring a wrongful death action.195 Since embryos are
earlier in the development process than nonviable fetuses, the argument follows that embryos would have no privilege to bring a wrongful death
action.196
V.
A.

STEM CELL REGULATIONS IN OTHER REGIONS

The European Union and Its Member States

The European Union (E.U.) is considered to have a restricted legal
framework in terms of
stem cell research regulation.197 However, its member nations have various regulations worth considering.198 Member nations do not have the power
to define what an embryo is, but they do have the power to interpret what is a
human embryo.199 The case of Evans v. United Kingdom ruled that no uniform legal status exists for human embryos within the E.U., leaving member
states to “doubt whether the organism is a human embryo.”200 The case of Vo
v. France created the “margin of appreciation” principle for the E.U. that
allows the member nations to interpret what a human embryo is based on
different cultural, moral, and philosophical ideals and circumstances.201
The European Patent Convention (EPC) was directed to harmonize patent laws throughout the E.U.202 An interesting element of the ECP is the
Morality Clause, which asserts that even if an invention fulfills the requirements to obtain a patent, the patent may still be rejected for morality reasons.203 Article 53(a) of the EPC states that patents will not be granted for
biotechnology inventions that concern the uses of human embryos for industrial or commercial purposes.204 Based on differing cultural and moral ideals,
members nations have adopted different interpretations of Article 53(a).205
Members states such as France, Italy, and the United Kingdom (U.K.) follow
the wording of the EPC in their laws, while other states broaden the moral
exclusion.206
195. Newhart, supra note 15, at 339.
196. Id. at 339–40.
197. See Jiang, supra note 11, at 57.
198. Id.
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The U.K. has permissive regulation for embryonic stem cell research,
however, their regulations are still moderate in comparison to other countries.207 The U.K.’s regulatory system for stem cell research is considered by
some as “one of the best in the world.”208 In 1990, the U.K. established a
national Human Fertilization and Embryology Authority to grant licenses to
researchers.209 In order to obtain a license for research under this act, an
applicant must demonstrate that (1) it is researching for the purpose of “promoting advances in the treatment of infertility. . . or developing [abnormality
detection] methods for. . . embryos pre-implementation”; and (2) “the activity is ‘necessary or desirable’ to achieve one of the specified purposes.”210
The particular wording of the 1990 Act did not explicitly permit stem cell
research and treatment but in 2001, the Parliament specified that a license
could be granted for the purposes of “(a) increasing knowledge about the
development of embryos[,] (b) increasing knowledge about serious disease,
or (c) enabling any such knowledge to be applied in developing treatments
for serious disease.”211 This specification was seen as a clear endorsement of
stem cell research by the U.K.’s government.212
Specifically, Great Britain’s policy on stem cell research is more permissible than most legislation found in the U.S.213 Great Britain’s policy includes restrictions much like the state of New Hampshire, such as a fourteenday post-fertilization age limit for an embryo to be used for research purposes, and also requires informed consent for the use of an embryo.214
Germany, which is notoriously “conservative about genetic research,”
has passed an act that allows embryonic stem cell research.215 Although it
allows stem cell research, German law remains extremely restrictive.216 The
German Embryo Protection Act (ESchG) prohibits the cultivation of more
than three embryos in order to protect human embryos, egg donation, and
pre-implantation genetic diagnosis.217 However, Germany does permit research on embryonic stem cells already harvested.218 In addition to the regulation stated above, Germany also has extensive regulation regarding the
207. See Rewerski, supra note 8, at 418.
208. Jiang, supra note 11, at 62.
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importation of human embryonic stem cells.219 Under the Stem Cell Act
(StZG), the basic principle stands that the importation and use of embryonic
stem cells is prohibited unless the following licensing conditions are met: (1)
the stem cells were extracted from surplus embryos via IVF before January 1,
2002; (2) the persons consented to the extraction of stem cells; (3) no remuneration or benefit of any kind was gained; and (4) no other regulations are
violated.220
The Netherlands takes up the middle ground between permissiveness
and prohibition for stem cell research as a result of political and commercial
balancing.221 The Netherlands, with their intermediate approach, forbids embryos to be created for research, however, it allows research to be done on
surplus IVF embryos.222 The potential issue with this intermediate approach
is that the policies are “at risk of being ambiguous and internally
inconsistent.”223
1.

Japan

Japan passed legislation in 2014 that simplified the clinical entry of cellbased products
for diseases and conditions so long as the product showed safety and
efficacy.224 This legislation allows a product or treatment to be provisionally
approved with the ability to withdraw provisional approval at any time, thus
allowing five years to amass enough clinical data for a proper efficacy review to be entertained.225 At that point, the entity claiming the treatment
would be able to petition for full approval by the Japanese regulatory authority.226 This system of clinical entry takes away the need for the expensive
phase III clinical trials required in the U.S., which keeps products out of
clinical use until there is full approval by the U.S. regulatory authority.227
While Japan’s simplified policies surrounding regenerative stem cell
medicine boosted its ranking in the medical industry, patients may be paying
the price.228 Just five years after adopting these simplified regulations, over
219. See id. at 72.
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221. Id. at 76–77.
222. Jiang, supra note 11, at 76.
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228. See David Cyranoski, The Potent Effects of Japan’s Stem-Cell Policies, NATURE (Oct. 10, 2019), https://www.nature.com/articles/d41586-019-02847-3
[https://perma.cc/E8ST-8BAJ].
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3,700 treatments were being offered at clinics across the country, making
Japan a “focal point for the development of innovative therapies.”229 However, a large concern emerges that companies may take advantage of the
meek regulatory paths to avoid any demanding testing of their treatment,
which might lower the chance of getting patients effective treatments.230
2.

China

China’s policy is one of the least restrictive in the world, and China has
Asia’s most extensive stem cell research industry.231 China allows embryonic
stem cell research and the production of new stem cell lines, which leads to
legal therapeutic cloning.232 Scientists in China work under the Ethical Guiding Principles on Human Embryonic Stem Cell Research, promulgated in
2003.233 While these principles act as guidelines for researchers, no legal or
criminal ramifications exist for violations of these principles.234 The Ethical
Guiding Principles require each institution researching stem cells create an
ethics committee, however, the prevalence of flexible ethical committees and
philosophies may explain China’s permissive policy regarding stem cells.235
3.

Australia

In July 2019, the Therapeutic Goods Administration (TGA) in Australia
implemented
new regulations in an attempt to lessen the potential harms of unproven
stem cell treatments while still maintaining patient access to proven therapies.236 These new regulations expanded the TGA’s oversight of products and
treatments derived from stem cells, requiring all non-hospital-based providers to comply with quality, efficacy, and safety requirements.237 This means
that any provider, even those obtaining cells for a patient’s own use, could
potentially face criminal penalties for providing unproven stem cell
treatments.238
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THE FUTURE OF STEM CELL RESEARCH IN THE U.S.

Medical Tourism

Medical tourism is the “act of going to another country to receive
healthcare treatment.”239 Medical tourism is not a new concept, in fact, there
is a long history and culture of
patients seeking and finding medical treatment in countries outside of
their own.240 In 2015 alone, around 1.25 million U.S. citizens sought medical
treatment abroad.241 This is not only common with patients but also with
researchers and doctors who seek out countries with regulatory systems that
provide them greater allowance to practice their specialties.242
There are several reasons why medical tourism exists, including cost,
availability, and most important in this case, legality.243 The U.S. healthcare
system has become too expensive for the uninsured and the underinsured,
which has encouraged U.S. citizens to seek treatment in other countries.244
Further, extensive regulation and a lack of funding in the U.S. has turned
patients to other countries for stem cell treatment.245 Other countries are benefiting financially from stem cell tourism, unfortunately this does not come
without costs to the patients.246 In countries with more permissive standards
than are present in the U.S., safety and effectiveness is a potential issue.247 In
order to combat the dangers of medical tourism, the U.S. should consider
new regulation that allows for better availability and access to safe stem cell
treatments domestically.248
B.

How Much Regulation Should There Be

There are strong arguments, from an institutional standpoint, in favor of
increasing the U.S. government’s regulation and funding of stem cell research.249 Too much regulation encourages research and treatment to occur
overseas, possibly pushing scientists and doctors to other countries, and lessens the ability of terminally ill patients to access experimental drugs.250 On
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the other hand, too little regulation allows harmful products into the market,
possibly opening the door for private companies to monopolize the field or
even black-market operations overtaking the benefits of such research.251 In
providing national regulations, the U.S. government has the ability to make
sure that embryonic stem cell research is not being abused.252 Instead, by
providing regulations the federal government could control the development
of stem cell research and who, when, and how scientists can reap its
benefit.253
C.

What Could be Incorporated From Other Regulatory Systems in
Forming a New System in the United States

In laboratory science, there is a saying that “not all experiments are
successful, but all experiments teach.”254 In this case, the different state variations on stem cell policies and regulatory systems in other countries can
teach the U.S. great lessons about what components are most desirable for a
future national policy.255
From the various states that have created policies that function within
considerable limits and oversight, the U.S. can see that research can be conducted even in areas complicated by varying religious and ethical concerns.256 In permissive states, policymakers can allow research in these
controversial areas with clearly established ethical guidelines.257 For example, the states in favor of embryonic stem cell research have found that any
reproductive cloning using embryonic stem cells is unacceptable, the buying
and selling of embryos is unacceptable, and any donations of embryos are
legal for research purposes so long as the donations are made with fully informed consent and rigorous procedures are followed.258 The U.S. can also
learn from the permissive states that the creation of an additional oversight
group that directly monitors embryonic stem cell research to assess breaches
and penalties could be a more immediate and effective method over the
threat of criminal penalties.259
Like California and other states who have created a new administrative
paradigm in support of stem cell research, the U.S. could place advisory
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power into the hands of qualified individuals.260 Instead of the current federal
model, where the political process and governmental agencies control the
administration of research funds, the U.S. could create new administrative
bodies made up of scientists and patient advocates.261 This change would
likely come with pushback that taking administration powers away from the
government is “an abdication of responsibility by the political sector.”262 But
there are also very obvious advantages that come along with a new administrative structure.263 Most importantly, scientists and patients generally possess the medical and industry specific expertise that legislative bodies often
lack.264 As it stands legislative bodies are politically pressured to make decisions that they are far removed from, while scientists and patients are on the
frontlines.265
Outside of the U.S., other countries provide various guides when it
comes to a national stem cell research policies. The U.S. could grant conditional approval of stem cell products after their safety has been demonstrated,
much like the regulation used in Japan.266 Like Japan, the U.S. could simplify
the clinical entry program to allow easier entry of cell-based products used to
advance medical research.267 Using a model like Japan’s could save anywhere from two to five years in approving stem cell products, and save tens
of millions of dollars in medical research by allowing provisional approval of
treatments.268 However, this kind of legislation would not come without its
challenges regarding ineffective treatments and safety issues, however, implementing other ethical and medical guidelines could lessen these
challenges.269
Like California and Great Britain, the U.S. could create a centralized
agency, whether it is run by the legislature or by scientists and patients,
which make grants and loans to researchers and monitors all activities related
to stem cell research.270 A centralized agency would provide a number of
benefits, including “encouraging cooperation, advocat[ing] for a common
cause, allowing for effective monitoring, and could ensure that different sorts
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of projects are pursued in a way that avoids too much overlap.”271 Additionally, a centralized agency could ensure that funds are spread across the nation
and implement greater adherence to certain ethical and medical standards.272
Lastly, a centralized agency would provide a combined front rather than the
current polarized state system currently in place.273
Like the U.K., the U.S. could create a federal licensing program.274 A
licensing program would promote cohesion and order in the current American system, and allow for the government to regulate the who, when, and
how of stem cell research.275 Unsurprisingly, a licensing program could create time delays in getting products to market, and would require extensive
research to weigh the benefits and costs of creating such a licensing
structure.276
Additionally, in order to promote the ethical standards discussed above,
the U.S. could prohibit compensation for stem cell donations, and place a
focus on informed consent.277 Like the state prohibitions on compensation for
selling and donating embryos in Massachusetts and California, the U.S. could
create a nation-wide compensation prohibition.278 The U.S. could implement
the policy that “donation should not be coerced or executed out of self-interest, [r]ather, the donation should be voluntary and incentive-free.”279 Further,
a regulation regarding informed consent could strengthen the above policy.280
This regulation is increasingly important because if individuals are not adequately informed about the decision whether or not to donate embryos, then
they would consequently be deprived of their “autonomous right to
choose.”281
VII.

CONCLUSION

There are a variety of routes that the U.S. could take in creating a new
legislation scheme regarding stem cell research. By comparing the successes
and failures of regulations in domestic states and abroad, a system that functions harmoniously in the U.S. can be pieced together. In focusing on prohibiting compensation for stem cell donations, informed consent from donors,
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and a federal licensing program the U.S. could regulate the use of stem cell
research in ways that increase safety and efficacy.282 While the available
routes the U.S. can choose to address the legality of stem cell research vary,
one thing is certain, the U.S. government and medical field need a coherent
national stem cell research policy to remain competitive in medicine and disease treatment, to decrease the need for medical tourism, and to provide effective and safe options for its citizens.283
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